Huntington National Bank Has $1.04 Million Stock Holdings in Celgene Co. (NASDAQ:CELG)
Huntington National Bank decreased its position in shares of Celgene Co. (NASDAQ:CELG) by 9.4% during the 2nd quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 11,269 shares of the biopharmaceutical company’s stock after selling 1,171 shares during the quarter. Huntington National Bank’s holdings in Celgene were worth $1,042,000 as of its most recent SEC filing.
A number of other large investors have also recently bought and sold shares of the business. Capital Management Corp VA bought a new stake in shares of Celgene during the 1st quarter valued at $10,955,000. Canyon Capital Advisors LLC bought a new stake in shares of Celgene during the 1st quarter valued at $119,226,000. Tibra Equities Europe Ltd bought a new stake in shares of Celgene during the 1st quarter valued at $6,396,000. Ruffer LLP bought a new stake in shares of Celgene during the 1st quarter valued at $226,613,000. Finally, Global Trust Asset Management LLC raised its position in shares of Celgene by 212.3% during the 1st quarter. Global Trust Asset Management LLC now owns 4,557 shares of the biopharmaceutical company’s stock valued at $430,000 after acquiring an additional 3,098 shares during the last quarter. 74.84% of the stock is currently owned by hedge funds and other institutional investors.
CELG has been the subject of several recent research reports. BidaskClub upgraded shares of Xilinx from a “hold” rating to a “buy” rating in a research report on Wednesday, July 24th. Zacks Investment Research cut shares of Phoenix New Media from a “hold” rating to a “sell” rating in a research report on Tuesday, July 23rd. ValuEngine cut shares of Zumiez from a “hold” rating to a “sell” rating in a research report on Tuesday, July 2nd. Sanford C. Bernstein restated a “sell” rating on shares of easyJet in a research report on Monday, April 1st. Finally, Mizuho set a $148.00 price objective on shares of Jazz Pharmaceuticals and gave the company a “hold” rating in a research report on Wednesday, July 3rd. Two investment analysts have rated the stock with a sell rating, sixteen have given a hold rating and four have issued a buy rating to the company. The stock presently has a consensus rating of “Hold” and a consensus target price of $94.81.
Celgene (NASDAQ:CELG) last released its earnings results on Thursday, April 25th. The biopharmaceutical company reported $2.55 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $2.45 by $0.10. The firm had revenue of $4.03 billion during the quarter, compared to analysts’ expectations of $4.01 billion. Celgene had a return on equity of 106.69% and a net margin of 30.10%. The company’s revenue was up 13.8% on a year-over-year basis. During the same quarter in the prior year, the company earned $2.05 EPS. Equities analysts expect that Celgene Co. will post 9.85 earnings per share for the current year.
Celgene Corporation, a biopharmaceutical company, discovers, develops, and commercializes therapies for the treatment of cancer and inflammatory diseases worldwide. It offers REVLIMID, an oral immunomodulatory drug for multiple myeloma (MM), myelodysplastic syndromes (MDS), and mantle cell lymphoma; POMALYST/IMNOVID to treat multiple myeloma; OTEZLA, a small-molecule inhibitor of phosphodiesterase 4 for psoriatic arthritis and psoriasis; and ABRAXANE to treat breast, non-small cell lung, pancreatic, and gastric cancers.
Read More: What is a Backdoor Roth IRA?
Receive News & Ratings for Celgene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celgene and related companies with MarketBeat.com's FREE daily email newsletter.